The Journal of Allergy and Clinical Immunology
Volume 121, Issue 4 , Pages 833-838 , April 2008

Issues in the diagnosis of α1-antitrypsin deficiency

  • Gary Rachelefsky, MD

      Affiliations

    • Executive Care Center for Asthma, Allergy, and Respiratory Diseases, UCLA Medical Center, Los Angeles, Calif
    • Corresponding Author InformationReprint requests: Gary Rachelefsky, MD, Executive Care Center for Asthma, Allergy, and Respiratory Diseases, UCLA Medical Center, 200 UCLA Medical Plaza, Suite 140-17, Los Angeles, CA 90095.
    • ,
  • D. Kyle Hogarth, MD

      Affiliations

    • Department of Medicine, Section of Pulmonary and Critical Care, University of Chicago, Chicago, Ill

Received 30 September 2007 ,Revised 22 November 2007 ,Accepted 28 December 2007.

References 

  1. Laurell CB, Eriksson S. The electrophoretic α1-globuli pattern of serum in α1-antitrypsin deficiency. Scand J Clin Lab Investigation. 1963;15:132–140
  2. Needham M, Stockley RA. Alpha 1-antitrypsin deficiency. 3: Clinical manifestations and natural history. Thorax. 2004;59:441–445
  3. American Thoracic Society–European Respiratory Society . American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168:818–900
  4. World Health Organization . Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health Organ. 1997;75:397–415
  5. de Serres FJ. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest. 2002;122:1818–1829
  6. de Serres FJ, Blanco I, Fernandez-Bustillo E. Estimating the risk for alpha-1 antitrypsin deficiency among COPD patients: evidence supporting targeted screening. COPD. 2006;3:133–139
  7. Campos MA, Wanner A, Zhang G, Sandhaus RA. Trends in the diagnosis of symptomatic patients with alpha1-antitrypsin deficiency between 1968 and 2003. Chest. 2005;128:1179–1186
  8. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet. 2005;365:2225–2236
  9. Crystal RG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest. 1990;85:1343–1352
  10. Dahl M, Tybjaerg-Hansen A, Lange P, Vestbo J, Nordestgaard BG. Change in lung function and morbidity from chronic obstructive pulmonary disease in alpha1-antitrypsin MZ heterozygotes: a longitudinal study of the general population. Ann Intern Med. 2002;136:270–279
  11. Sveger T, Piitulainen E, Arborelius M. Lung function in adolescents with alpha 1-antitrypsin deficiency. Acta Paediatr. 1994;83:1170–1173
  12. Thelin T, Sveger T, McNeil TF. Primary prevention in a high-risk group: smoking habits in adolescents with homozygous alpha-1-antitrypsin deficiency (ATD). Acta Paediatr. 1996;85:1207–1212
  13. Wall M, Moe E, Eisenberg J, Powers M, Buist N, Buist AS. Long-term follow-up of a cohort of children with alpha-1-antitrypsin deficiency. J Pediatr. 1990;116:248–251
  14. Bernspang E, Sveger T, Piitulainen E. Respiratory symptoms and lung function in 30-year-old individuals with alpha-1-antitrypsin deficiency. Respir Med. 2007;101:1971–1976
  15. Carpenter MJ, Strange C, Jones Y, Dickson MR, Carter C, Moseley MA, et al. Does genetic testing result in behavioral health change? Changes in smoking behavior following testing for alpha-1 antitrypsin deficiency. Ann Behav Med. 2007;33:22–28
  16. Gitter AC, Jones Y, Schwartz L, Peterka L, Brantly M, Strange C. Confidential home alpha-1 antitrypsin testing: specialty center support for rare diseases. Presented at: ATS annual meeting; May 18-23, 2007; San Francisco, Calif.
  17. Stoller JK, Smith P, Yang P, Spray J. Physical and social impact of alpha 1-antitrypsin deficiency: results of a survey. Cleve Clin J Med. 1994;61:461–467
  18. Piitulainen E, Sveger T. Effect of environmental and clinical factors on lung function and respiratory symptoms in adolescents with alpha1-antitrypsin deficiency. Acta Paediatr. 1998;87:1120–1124
  19. Piitulainen E, Eriksson S. Decline in FEV1 related to smoking status in individuals with severe alpha1-antitrypsin deficiency (PiZZ). Eur Respir J. 1999;13:247–251
  20. Demeo DL, Sandhaus RA, Barker AF, Brantly ML, Eden E, McElvaney NG, et al. Determinants of airflow obstruction in severe alpha 1- antitrypsin deficiency. Thorax. 2007;62:806–813
  21. Senn O, Russi EW, Imboden M, Probst-Hensch NM. alpha1-Antitrypsin deficiency and lung disease: risk modification by occupational and environmental inhalants. Eur Respir J. 2005;26:909–917
  22. Alpha-1 Foundation. A healthcare provider's guide to alpha-1 antitrypsin deficiency. Version 1.6. Miami (FL): Alpha-1 Foundation; 2007.
  23. Strange C, Stoller JK, Sandhaus RA, Dickson R, Turino G. Results of a survey of patients with alpha-1 antitrypsin deficiency. Respiration. 2006;73:185–190
  24. McElvaney NG, Stoller JK, Buist AS, Prakash UB, Brantly ML, Schluchter MD, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest. 1997;111:394–403
  25. Hogarth DK. Testing for α1-antitrypsin deficiency in patients with asthma and/or chronic obstructive pulmonary disease: a surveillance study. Presented at: American College of Chest Physicians meeting; October 20-25, 2007; Chicago, Ill.
  26. Sveger T, Ohlsson K, Piitulainen E. Adolescents with alpha1-antitrypsin deficiency have high alpha2-macroglobulin and low neutrophil lipocalin and elastase levels in plasma. Pediatr Res. 1998;44:939–941
  27. Norman MR, Mowat AP, Hutchison DC. Molecular basis, clinical consequences and diagnosis of alpha-1 antitrypsin deficiency. Ann Clin Biochem. 1997;34(suppl):230–246
  28. Sveger T, Thelin T, McNeil TF. Neonatal alpha1-antitrypsin screening: parents' views and reactions 20 years after the identification of the deficiency state. Acta Paediatr. 1999;88:315–318
  29. Sveger T, Thelin T, McNeil TF. Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition. Acta Paediatr. 1997;86:37–40
  30. Improving the implementation of alpha-1 diagnosis guidelines in clinical practice. Presented at: Advisory Forum; June 24-26, 2005; Las Vegas, Nev.
  31. Brantly ML, Wittes JT, Vogelmeier CF, Hubbard RC, Fells GA, Crystal RG. Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest. 1991;100:703–708
  32. Brantly M. Efficient and accurate approaches to the laboratory diagnosis of alpha1-antitrypsin deficiency: the promise of early diagnosis and intervention. Clin Chem. 2006;52:2180–2181
  33. Bals R, Koczulla R, Kotke V, Andress J, Blackert K, Vogelmeier C. Identification of individuals with alpha-1-antitrypsin deficiency by a targeted screening program. Respir Med. 2007;101:1708–1714
  34. Strange C, Moseley MA, Jones Y, Schwarz L, Xie L, Brantly ML. Genetic testing of minors for alpha1-antitrypsin deficiency. Arch Pediatr Adolesc Med. 2006;160:531–534
  35. Snyder MR, Katzmann JA, Butz ML, Yang P, Dawson DB, Halling KC, et al. Diagnosis of alpha-1-antitrypsin deficiency: an algorithm of quantitation, genotyping, and phenotyping. Clin Chem. 2006;52:2236–2242
  36. Alpha-1 Foundation. What is alpha-1 antitrypsin deficiency? Version 1 (1/06). Miami (FL): Alpha-1 Foundation; 2007.
  37. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532–555
  38. Dirksen A, Stockley RA, Piitulainen E, Shaker SB, Bernhardt T. A randomized, placebo-controlled, double-blind, exploratory study of the effect of augmentation therapy in patients with severe alpha-1 antitrypsin deficiency (AATD) and chronic obstructive pulmonary disease (COPD). Presented at: ATS annual meeting; May 18-23, 2007; San Francisco, Calif.
  39. Louie SG, Sclar DA, Gill MA. Aralast: a new alpha1-protease inhibitor for treatment of alpha-antitrypsin deficiency. Ann Pharmacother. 2005;39:1861–1869
  40. Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J. 1997;10:2260–2263
  41. Stocks JM, Brantly M, Pollock D, Barker A, Kueppers F, Strange C, et al. Multi-center study: the biochemical efficacy, safety and tolerability of a new α1-proteinase inhibitor, Zemaira®. COPD. 2006;3:17–23
  42. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. Am J Respir Crit Care Med. 1998;158:49–59
  43. Wencker M, Fuhrmann B, Banik N, Konietzko N. Longitudinal follow-up of patients with alpha(1)-protease inhibitor deficiency before and during therapy with IV alpha(1)-protease inhibitor. Chest. 2001;119:737–744
  44. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med. 1999;160:1468–1472
  45. Parr DG, Stoel BC, Stolk J, Stockley RA. Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency. Thorax. 2006;61:485–490
  46. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report—2006. J Heart Lung Transplant. 2006;25:880–892
  47. Stoller JK, Gildea TR, Ries AL, Meli YM, Karafa MT. Lung volume reduction surgery in patients with emphysema and alpha-1 antitrypsin deficiency. Ann Thorac Surg. 2007;83:241–251

 Disclosure of potential conflict of interest: G. Rachelefsky has consulting arrangements with AstraZeneca, CSL Behring, Schering-Plough, Merck, Medpointe, Forest Labs, Teva, and Asubiopharm and is on the speakers' bureau for AstraZeneca, Schering-Plough, Merck, Teva, and Genentech. D. K. Hogarth is on the speakers' bureau for CSL Behring, Talecris, and Baxter; has received research support from CSL Behring and Baxter; and has served as an expert witness on α1-antitrypsin.

PII: S0091-6749(08)00125-5

doi: 10.1016/j.jaci.2007.12.1183

The Journal of Allergy and Clinical Immunology
Volume 121, Issue 4 , Pages 833-838 , April 2008

Article Tools

* Image Usage & Resolution